Fluidigm closes $63M stock offering

Fluidigm announces closing of public offering of 9,372,500 shares of common stock including full exercise of option to purchase additional shares. Fluidigm a player in mass cytometry and microfluidics technologies, announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock.

The stock was sold at a price to the public of $6.75 per share, for aggregate gross proceeds of approximately $63.3 million, from the company’s existing shelf registration statement. The shares include 1,222,500 shares of common stock sold pursuant to an over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. Net proceeds from the offering were approximately $59.1 million after deducting underwriting discounts and commissions and the estimated expenses of the offering. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.